Synaffix, a Netherlands-based biotechnology company exclusively focused on the development of an antibody-drug conjugate (ADC) technology, says its newly built high potency laboratory is now fully operational.
The lab is designed to facilitate the synthetic modification and safe handling of the most potent anti-cancer payloads and their site-specific attachment to antibodies. This recent advancement enables Synaffix to generate gram-scale batches of ADCs for preclinical use.
Synaffix has two proprietary technology platforms, GlycoConnect and HydraSpace, which expand the therapeutic index (TI) of ADCs without the need for antibody engineering, while retaining the versatility to use any IgG isotype and payload class.
'The installation of our high potency laboratory marks an important event in the evolution of our R&D capabilities here at Synaffix. Coupled with the pre-existing speed of our GlycoConnect technology to generate ADC material as fast as a couple of weeks, the increased scale and ongoing commitment to safety will further enhance our ability to support the growing number of collaborations with biotech and pharma companies,' said Floris van Delft, Chief Scientific Officer of Synaffix.
